Kymera Therapeutics KYMR Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's accounts payable?
- Kymera Therapeutics (KYMR) reported accounts payable of $12.84M in Q1 2026.
- How has Kymera Therapeutics's accounts payable changed year-over-year?
- Kymera Therapeutics's accounts payable increased by 25.1% year-over-year, from $10.26M to $12.84M.
- What is the long-term trend for Kymera Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Kymera Therapeutics's accounts payable has grown at a -1.7% compound annual growth rate (CAGR), from $4.37M to $4.02M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.